{"id":"c0aa54d6-8f64-5f0c-a221-dea00fbb856d","stable_key":"c94a9824-35fb-523c-b421-dc7341218dcb:indicaxanthin-cisplatin-apoptosis","predicate":"potentiates","statement":"Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"b87a7b38-83bb-54d4-a805-eeadb74f7982","mechanism_event_label":"Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.","subject":{"id":"f2a6e469-05f0-5596-9054-da926389f584","slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"},"object":{"id":"37c05fb4-b56e-545f-8515-aec08678e90e","slug":"human-hela-apoptosis","display_name":"Apoptosis in human HeLa cervical cancer cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"b87a7b38-83bb-54d4-a805-eeadb74f7982","stable_key":"c94a9824-35fb-523c-b421-dc7341218dcb:indicaxanthin-cisplatin-apoptosis-event","event_type":"observed_relationship","label":"Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.","description":"Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"f2a6e469-05f0-5596-9054-da926389f584","slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"37c05fb4-b56e-545f-8515-aec08678e90e","slug":"human-hela-apoptosis","display_name":"Apoptosis in human HeLa cervical cancer cells","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"bdb83796-78cf-5b54-9ca6-4dab19b33600","slug":"cisplatin","display_name":"Cisplatin","entity_type_key":"drug"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Indicaxanthin 60 micromolar with cisplatin 10 micromolar; individual-agent controls","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"24 h","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary open full text, relevant results/methods and PubMed metadata.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human HeLa cervical cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Cell-culture chemosensitization is not clinical cancer efficacy. Redox-probe signals and protein changes do not prove direct target binding.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Dedicated indicaxanthin chapter; original betalain family identity and shared claims preserved.","comparator":null,"unit":null,"notes":"","entity":{"slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human HeLa cervical cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Co-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro co-treatment","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Cell death and redox assays","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"44063a3a-8c30-5573-a252-4fecafea2bcd","evidence_kind":"source_excerpt","locator":"Lines 283-292","start_line":283,"end_line":292,"excerpt":"## indicaxanthin-cisplatin-apoptosis\nCo-treatment with indicaxanthin increased cisplatin-associated apoptosis in HeLa cells relative to cisplatin alone.\nModel/species: Human HeLa cervical cancer cells\nTissue: Cell death and redox assays\nExposure: Indicaxanthin 60 micromolar with cisplatin 10 micromolar; individual-agent controls\nRoute: In vitro co-treatment\nDuration: 24 h\nLimits: Cell-culture chemosensitization is not clinical cancer efficacy. Redox-probe signals and protein changes do not prove direct target binding.\nPrimary reference: The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994\nAccess: Primary open full text, relevant results/methods and PubMed metadata.","model_system":"Human HeLa cervical cancer cells","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact archived curation span; original paraphrase with primary citation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"18b7303c-98b7-54cb-ae8e-a8c6257657b1","stable_key":"import-c94a9824-35fb-523c-b421-dc7341218dcb","title":"Indicaxanthin: mechanisms, molecular forms and cross-actor connections (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted curation of thirteen additional primary studies, with twenty-six existing claims from eight studies linked unchanged. Study-specific citations and limitations retained. Not publisher full text.","file_path":"","sha256":"fd5e7b3a108073af5a8cad0e226a483ae2cda3b0e1daed387553ee441acecd5f","revision_id":"f3357c22-1be7-5502-b4f5-415d19c3cf5a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}